Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2002

Primary Completion Date

January 31, 2005

Study Completion Date

June 30, 2005

Conditions
Leukemia
Interventions
BIOLOGICAL

denileukin diftitox

Trial Locations (11)

27534

Southeastern Medical Oncology Center, Goldsboro

29303

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg

37404

Chattanooga Oncology and Hematology Associates, Chattanooga

47591

Medical Center Vincennes, Vincennes

48202

Josephine Ford Cancer Center at Henry Ford Health System, Detroit

60611

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

70360

Cancer Care Specialists, Houma

78705

Southwest Regional Cancer Center - Central, Austin

92868-3849

St. Joseph Hospital Regional Cancer Center - Orange, Orange

71130-3932

Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport

27157-1082

Comprehensive Cancer Center at Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT00082940 - Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter